Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 – CMI – GlobeNewswire

Posted: April 28, 2020 at 2:46 pm

SEATTLE, April 23, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is estimated to be valued at US$ 43,205.8 million in 2020, and is expected to exhibit a CAGR of 12.7% during the forecast period (2020-2027).

Key Trends:

Key trends in the market include viral disease outbreaks, the increasing prevalence of chronic lymphocytic leukemia, and demand for immune globulin products in the market.

According to the American Cancer Society around 60,530 new cases of leukemia will be diagnosed in the U.S in 2020 out of which 21,040 new cases will be of chronic lymphocytic leukemia (CLL).

Similarly, according to the Cancer Research UK, around 3,500 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in the U.K in 2017.

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/3790

Moreover, the growing demand for immune globulin (IG) products is expected to drive the human immunoglobulin (ph4) for intravenous injection (COVID-19) market growth. For instance, on August 12, 2019, the U.S. Food and Drug Administration (FDA) confirmed that demand for immune globulin products has increased in recent years and there is a shortage of Immune Globulin (Subcutaneous) (IGSC) and Immune Globulin (Intravenous) (IGIV) products in the U.S. The U.S. Food and Drug Administration is working closely with manufacturers such as Asceniv, Bivigam, Octagam, Panzyga, Privigen and others of various immune globulin (intravenous) (IGIV) products to help mitigate the supply situation for IG products.

Key Market Takeaways:

Key players operating in market are

Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc., China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.

Buy this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3790

Market Segmentation:

Related Topics:

HEALTHCARE CONTRACT RESEARCH OUTSOURCING MARKET

Healthcare Contract Research Outsourcing is conducted by pharmaceutical and medical device sectors for development of new drugs and medical devices. Clinical trials form the key part of pharmaceutical drug and medical device development and in the current scenario clinical trials are conducted across multiple locations in various geographies. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.

Read more @ https://www.coherentmarketinsights.com/market-insight/healthcare-contract-research-outsourcing-market-3788

ANDROGEN REPLACEMENT THERAPY MARKET

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level.

Read more @ https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787

Read the original:
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 - CMI - GlobeNewswire

Related Post

Comments are closed.

Archives